BioSpace News Archive

Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of September.

Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology.

BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) (“BioVaxys” or “the Company”), is pleased to announce that it has further extended its research collaboration with The Ohio State University (“The Ohio State”) for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine research.

Medicure Inc. reaffirms its commitment to providing affordable and straightforward access to its branded pitavastatin, ZYPITAMAG®, to people living with HIV through two important channels: its pharmacy subsidiary Marley Drug® and through the AIDS Drug Assistance Program Crisis Task Force formulary.

BioSkryb Genomics announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces the U.S. Food and Drug Administration has granted Orphan Drug Designation to its wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia.

Valneva SE announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single-shot chikungunya vaccine candidate VLA1553 in persons aged 18 years and above, and has determined that the New Drug Submission application is sufficiently complete to permit a substantive review.

Orexo AB, announces that the United States Patent and Trademark Office has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, confirmed that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.

Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, announced that the Egyptian Drug Authority has approved the manufacturing and distribution of AVT02 a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases, under the trade name Adalimumab-EVA™.